The highest mutation frequency of BRAF, ATRX, IDH1, CDKN2A, and EGFR was seen in melanoma (SKCM), thyroid carcinoma (THCA), brain lower-grade glioma (LGG), head and neck squamous cell carcinoma (HNSC), and glioblastoma multiforme (GBM), respectively (Figs. S2B, S4C). Here, CDKN2A is linked to melanoma.